Dr. Tashko’s Medical Activity
Presenter at the 2019 Diabetes Symposium
I wish to thank Dr. Mihail “Misha” Zilbermint and Dr. Shabina R. Ahmed for inviting me to present at the 2019 Diabetes Symposium of Suburban Hospital, a member of Johns Hopkins Medicine. The symposium was a meaningful educational activity discussing the latest progress in the field of clinical diabetology. Over 100 primary care providers attended the seminar. The topic of my presentation was “Modern lipid approach in patients with diabetes.” Experts discussed in detail various…
Published
Obesity Medicine
Harvard Medical School offers an unparalleled opportunity to learn cutting-edge developments in the field of research and clinical obesity. Numerous subjects were discussed in detail. Topics ranged from molecular biology, genetics, and hormonal feedbacks to clinical, neuropsychological, and surgical interventions to nutritional, epidemiological, and public health. GT
Published
Reasoning
Guidelines do not say how to read between the lines. Experience, judgment, and reasoning do. – Dr. Tashko
Published
Certified Lipidologist
I am pleased to announce that, as of October 2018, I am a certified clinical lipidologist, accredited by the American Board of Clinical Lipidology (ABCL). The role of the lipidologist is to diagnose, treat, and manage patients with elevated cholesterol or triglyceride levels. Currently, there are approximately 700 certified lipidologists in the U.S. Dyslipidemia is a major public health concern. Elevated cholesterol levels, particularly what’s called the “bad” cholesterol (LDLc) or non-HDL cholesterol are major…
Published
Categorized as Blog, Dr. Tashko’s Medical Activity, Heart Health, Insights from Dr. Tashko, Lipid Health
Honored to be selected again as a Washingtonian Top Doctor, 2018
I am humbled and honored to be selected again by my peers as one of the 2018 Washingtonian Top Doctors in endocrinology. It is a wonderful opportunity to work closely with my fellow physicians and care for my patients in the greater Washingtonian area. GT
Published
The two great days
There are two great days in a person’s life; the day we are born and the day we discover why William Barclay
Published
Merit-based payment for blood pressure care
I am happy to contribute to the editorial by Lisa Eramo published in Medical Economics, January 2018. The article is important as it raises physician awareness of Merit-based Incentive Payment System (MIPS) under which hypertension management falls. MIPS, part of 2015 MACRA, will go into effect in 2019. GT
Published
Honored to be selected as a Washingtonian Top Doctor, 2017
I am humbled and honored to be selected by my peers as one of the 2017 Washingtonian Top Doctors in endocrinology. It’s a wonderful opportunity to work closely with my fellow physicians and care for my patients in the greater Washingtonian area. GT
Published
An overview of new hypertension guidelines
New definitions: Normal BP: <120/80 mmHgElevated BP “Pre HTN”: 120-130/<80Stage 1 HTN: 130-140/80-90Stage 2 HTN: >140/90 New targets for treatment: If ASCVD 10-year-risk is <10%, then target BP <140/90If ASCVD 10-year-risk is ≥10%, then target BP <130/80 Established CVDDIABETESCKDAGE>65 and “healthy” GT
Published
Categorized as Blog, Clinical Guidelines, Dr. Tashko’s Medical Activity, Hypertension, Insights from Dr. Tashko
Recombinant PTH for Chronic Primary Hypoparathyroidism
Primary hypoparathyroidism (PHPT) is a rare endocrine condition defined by hypocalcemia and deficient parathyroid hormone (PTH). It is primarily managed with high dose oral calcium and vitamin D supplementation instead of targeting the root cause of deficient PTH. Conventional treatment is difficult to manage and often inadequate at controlling symptoms and preventing complications. RhPTH (1-84) is a recombinant form of PTH that acts as a direct substitute to the native hormone. It is a novel…
Published
Metformin and CVD prevention
Recent literature suggests that early metformin use could help reduce CVD progression and outcomes in patients with prediabetes and type 2 diabetes beyond glycemic control. It is important to discuss this information with individuals who are in the prediabetic or early diabetic stages of the disease, A1c 5.7-7.0%. Benefits should be weighed against metformin adverse effects, polypharmacy, life expectancy and comorbidities, particularly in the setting of cardiac, renal or hepatic pathology. Individualized patient discussion and…
Published
Categorized as Blog, Diabetes Care, Dr. Tashko’s Medical Activity, Heart Health, Insights from Dr. Tashko
National Lipid Association, Interview
Happy to be a member of National Lipid Association (NLA). My involvement with NLA has generated a small contribution to the LipidSpin edition, May 2017. Thank you NLA and Dr. Paul Ziajka! GT
Published